By Dominic Chopping 
 

Danish pharmaceutical company Novo Nordisk A/S said Friday that it has submitted a new drug application to the U.S. Food and Drug Administration for its semaglutide weight-loss drug.

"Obesity is associated with a wide range of serious complications, yet many healthcare providers still do not have sufficient medical options available to help people with this chronic disease," said Novo Nordisk Chief Scientific Officer Mads Krogsgaard Thomsen.

Semaglutide is a glucagon-like peptide-1 drug, or GLP-1, that helps enhance the production of insulin and regulate appetite.

Novo Nordisk said it expects the review of its application to complete in six months.

 

Write to Dominic Chopping at dominic.chopping@wsj.com

 

(END) Dow Jones Newswires

December 04, 2020 08:22 ET (13:22 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.